On October 2, 2012, the company was charged with a $500 million fine and $ million forfeiture for illegal marketing, and in a plea agreement was assessed the second-largest criminal fine in . history for a drug company. District Court Judge Samuel G Wilson of the Western District of Virginia imposed it given Abbott's guilty plea related to its unlawful promotion of Depakote for uses not approved by the FDA. Abbott had advertised Depakote to be used to control behavioral disturbances for patients with dementia and schizophrenia, without FDA approval. In addition, Abbott marketed Depakote for other psychiatric conditions in adults, including depression, anxiety, obsessive-compulsive disorder, post-traumatic stress disorder, alcohol and drug withdrawal and psychiatric conditions in children, including conduct disorders, attention deficit disorder and autism. The court also ordered Abbott to a five-year term of probation and court supervision.  Shareholders then brought derivative suits against the company directors for breach of fiduciary duty  The parties reached a negotiated settlement in which Abbott agreed to beef up its internal controls and paid the plaintiffs' attorney fees.